Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Endocrinology Drugs Market Size Changed, over the years?

The market for endocrinology drugs has seen significant expansion in past years. The prediction indicates a rise from $33.26 billion in 2024 to $36.21 billion in 2025, with a compound annual growth rate (CAGR) of 8.86%. Factors contributing to the growth during the historical period include the growing global occurrence of diabetes, government initiatives, increased healthcare spending, a higher rate of adrenal gland disorders, increased demand for insulin analogs, and an increase in the number of endocrinologists.

How Much Will the Endocrinology Drugs Market Be Worth in 2029?

Expectations are high for the endocrinology drugs market to witness robust growth in the upcoming years, swelling to a valuation of $50.37 billion by 2023 with a Compound Annual Growth Rate (CAGR) of 8.60%. The surge anticipated in the forecast timeframe is due to an escalating diabetic populace, an increased incidence of endocrine disorders, a rise in the number of adolescents confronting hormonal imbalances and mounting obesity figures. Noteworthy trends predicted during the forecast period encompass technological upgradation, adoption of revolutionary drug delivery systems, the inclusion of digital health solutions, precision medicine, and amalgamated therapies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20769&type=smp

Which is the Largest Company in the Endocrinology Drugs Market?

Major companies operating in the endocrinology drugs market are Johnson & Johnson Inc., Merck & Co. Inc., AbbVie Inc., Bayer Aktiengesellschaft, Novartis International AG, Sanofi S.A., AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Biocon Limited, Boehringer Ingelheim International GmbH, Mylan N.V., Sandoz International GmbH, Ipsen Pharma, Ferring Pharmaceuticals Inc., Endocrine Pharma Private Limited

What Are the Main Market Drivers in the Endocrinology Drugs Industry?

An increase in the number of cases of endocrine diseases is expected to boost the endocrinology drugs market. Endocrine disorders disrupt the endocrine system, resulting in either overproduction or underproduction of hormones, which can hinder normal bodily functions. This surge in endocrine diseases has been put down to several influencers including lifestyle changes, an aging demographic, and better diagnostics, all of which have shed more light on these ailments increasing their diagnosed cases. Endocrinology drugs function by moderating hormone concentrations, addressing gland issues, and reestablishing hormonal equilibrium to decrease symptoms and improve total health. For example, the National Library of Medicine, a medical library based in the US, reported in May 2023 that an estimated 13 million people or 4.78% of the population in the US are suffering from unrecognized endocrine disorders. Thyroid disease is among the most frequently occurring endocrine disorders, making up roughly 30% to 40% of patients treated in endocrine procedures. Consequently, the growth of endocrine diseases is fuelling the expansion of the endocrinology drugs market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=20769&type=smp

How Is the Endocrinology Drugs Market Segments Structured?

The endocrinology drugs market covered in this report is segmented –

1) By Indication: Hyperthyroidism, Hypothyroidism, Diabetes, Polycystic Ovarian Syndrome, Growth Hormone Disorders, Pituitary Gland Disorders, Other Indications

2) By Therapy Area: Diabetes Drugs, Thyroid Hormone Disorder Drugs, Human Growth Hormone, Testosterone Replacement Therapy, Others Therapy Areas

3) By Distribution Channel: Hospital pharmacies, Online Pharmacies, Retail pharmacies

4) By End User: Hospitals, Ambulatory Surgical Centers, Others End Users

Subsegments:

1) By Hyperthyroidism: Antithyroid Medications, Radioactive Iodine Therapy, Beta Blockers

2) By Hypothyroidism: Levothyroxine-based Medications, Liothyronine-based Medications, Combination Hormonal Therapies

3) By Diabetes: Insulin Therapies, Oral Antidiabetic Drugs (OADs), GLP-1 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors

4) By Polycystic Ovarian Syndrome (PCOS): Oral Contraceptives, Metformin, Clomiphene Citrate, Anti-Androgens

5) By Growth Hormone Disorders: Recombinant Human Growth Hormone (rhGH), Growth Hormone Secretagogues, Growth Hormone Receptor Antagonists

6) By Pituitary Gland Disorders: Somatostatin Analogs, Gonadotropins, Dopamine Agonists

7) By Other Indications: Adrenal Gland Disorders, Osteoporosis, Parathyroid Disorders, Male Hormonal Imbalances

What Strategic Trends Are Transforming the Endocrinology Drugs Market?

In an attempt to improve medication administration, major players in the endocrine drugs industry are concentrating their efforts on creating innovative products, such as ready-to-use vials. These vials, which are pre-filled and pre-dosed, don’t need any preparation or reconstitution before being administered. A perfect example of this is the launch of the Levothyroxine sodium injection in ready-to-use vials by Hikma Pharmaceuticals plc, a pharmaceutical firm based in the UK, in December 2022. The product, which has a concentration of 100 mcg/mL, is immediately usable, doing away with the need for reconstitution and cutting down the chances of mistakes during preparation, therefore enhancing patient safety. The offering ensures accurate and stable dosing, which is crucial for treating disorders such as hypothyroidism and myxedema coma. The ready-to-use vials also enhance the efficiency of healthcare providers by saving time and ensuring correct administration in emergency care situations.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/endocrinology-drugs-global-market-report

Which Global Regions Offer the Highest Growth in the Endocrinology Drugs Market?

North America was the largest region in the endocrinology drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the endocrinology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20769

This Report Delivers Insight On:

1. How big is the endocrinology drugs market, and how is it changing globally?

2. Who are the major companies in the endocrinology drugs market, and how are they performing?

3. What are the key opportunities and risks in the endocrinology drugs market right now?

4. Which products or customer segments are growing the most in the endocrinology drugs market?

5. What factors are helping or slowing down the growth of the endocrinology drugs market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model